Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HNRNPA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HNRNPA1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed by MS. |
View HNRNPA1 Products |
| Gene Delivery | HNRNPA1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cytoplasmic accumulation assays. |
View HNRNPA1 Products |
| Benchmark Ab | Anti-HNRNPA1 Recombinant Antibody Recombinant positive control for western blot, IHC, and IP validation. |
View HNRNPA1 Products |
| Validator | HNRNPA1 siRNA Set For knockdown verification in alternative splicing and target validation assays. |
View HNRNPA1 Products |
| Related Target A | TNPO1 Transportin-1, the primary nuclear import receptor for HNRNPA1; critical for nuclear-cytoplasmic transport and ALS pathology modeling. |
View TNPO1 Products |
| Related Target B | PKM2 Pyruvate Kinase M2, a downstream splicing target of HNRNPA1 driving the Warburg effect in cancer cells. |
View PKM2 Products |
| Related Target C | TARDBP TDP-43, which co-aggregates with HNRNPA1 in neurodegenerative diseases; critical for comparative proteinopathy studies. |
View TARDBP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Assaying RNA-Binding Domain (RBD) Interactions | High Purity (>95% by SDS-PAGE) recombinant HNRNPA1 ensuring low background noise in Fluorescence Polarization (FP) and SPR assays. |
| Modulating Cytoplasmic Aggregation (ALS/FTD) | Lentivirus-mediated expression for stable delivery, avoiding transient transfection artifacts in stress granule recruitment assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HNRNPA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HNRNPA1 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic mechanisms to RNA-binding protein (RBP) modulators and targeted protein degraders (PROTACs). As first-generation splicing modulators reach preclinical and early clinical milestones, the next wave of R&D is targeting the protein-protein interaction (PPI) interface between HNRNPA1 and its nuclear import receptors, as well as preventing pathological aggregation in neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Splicing Modulator) | PTC Therapeutics, Roche, Academic Consortia | Spinal Muscular Atrophy, Colorectal Cancer | In vitro RNA-binding assays (Need sequence-verified, high-purity recombinant HNRNPA1) |
| PROTAC / Degrader | Preclinical Biotech, Arvinas (Target exploration) | Solid Tumors, Glioma | Target degradation kinetics (Need high-purity proteins for SPR/FP and siRNA for control) |
| Oligonucleotide (ASO / siRNA) | Ionis Pharmaceuticals, Alnylam | ALS, Frontotemporal Dementia (FTD) | Expression knockdown validation (Need stable cell line construction via Lentivirus) |